Skip to main content

03-06-2019 | Non-small cell lung cancer | ASCO 2019 | Article

Researcher comment: 5-year KEYNOTE-001 results show long-lasting survival for some advanced NSCLC patients

Conference coverage direct to your inbox

Edward Garon presents the 5-year follow-up results of the advanced non-small-cell lung cancer cohort of the phase I KEYNOTE-001 trial of pembrolizumab monotherapy (4:12).

Back to the conference hub

Related topics

More on this topic

Image Credits